146 related articles for article (PubMed ID: 33648663)
1. Critical Role of 2-[18F]-fluoro-2-deoxy-glucose in Hormonally Active Malignancies.
Yadav D; Kumar R
PET Clin; 2021 Apr; 16(2):177-189. PubMed ID: 33648663
[TBL] [Abstract][Full Text] [Related]
2. Molecular Imaging Assessment of Hormonally Sensitive Breast Cancer: An Appraisal of 2-[18F]-Fluoro-2-Deoxy-Glucose and Newer Non-2-[18F]-Fluoro-2-Deoxy-Glucose PET Tracers.
Yadav D; Kumar R; Phulia A; Basu S; Alavi A
PET Clin; 2022 Jul; 17(3):399-413. PubMed ID: 35717099
[TBL] [Abstract][Full Text] [Related]
3. [The value of 18F-fluoro-2-deoxy-D-glucose positron emission tomography (18F-FDG PET) in diagnosis of neoplastic diseases].
Ruiz Hernández G; Romero de Avila Y Avalos C; Carreras Delgado JL
Med Clin (Barc); 2005 Feb; 124(6):229-36. PubMed ID: 15737307
[TBL] [Abstract][Full Text] [Related]
4. Scintigraphy with [18F]2-fluoro-2-deoxy-D-glucose of cancer patients.
Paul R; Roeda D; Johansson R; Ahonen A; Haaparanta M; Solin O; Sipilä H
Int J Rad Appl Instrum B; 1986; 13(1):7-12. PubMed ID: 3771240
[TBL] [Abstract][Full Text] [Related]
5. Cancer detection with whole-body PET using 2-[18F]fluoro-2-deoxy-D-glucose.
Hoh CK; Hawkins RA; Glaspy JA; Dahlbom M; Tse NY; Hoffman EJ; Schiepers C; Choi Y; Rege S; Nitzsche E
J Comput Assist Tomogr; 1993; 17(4):582-9. PubMed ID: 8331230
[TBL] [Abstract][Full Text] [Related]
6. Tumor diagnosis by PET: potential of seven tracers examined in five experimental tumors including an artificial metastasis model.
Ishiwata K; Takahashi T; Iwata R; Tomura M; Tada M; Itoh J; Kameyama M; Ido T
Int J Rad Appl Instrum B; 1992 Aug; 19(6):611-8. PubMed ID: 1387872
[TBL] [Abstract][Full Text] [Related]
7. [Uptake of FDG (2-fluoro-2-deoxy-D-glucose) as a tumor imaging agent into erythrocytes and accumulation of FDG in tumor cells].
Minosako Y; Nemoto M; Ino S; Shirakami Y; Kurami M
Kaku Igaku; 2003 Feb; 40(1):23-30. PubMed ID: 12701204
[TBL] [Abstract][Full Text] [Related]
8. Clinical utility of FDG PET.
Otsuka H; Graham M; Kubo A; Nishitani H
J Med Invest; 2004 Feb; 51(1-2):14-9. PubMed ID: 15000251
[TBL] [Abstract][Full Text] [Related]
9. Comparison of Positron Emission Tomography Using 2-[18F]-fluoro-2-deoxy-D-glucose and 3-deoxy-3-[18F]-fluorothymidine in Lung Cancer Imaging.
Wang FL; Tan YY; Gu XM; Li TR; Lu GM; Liu G; Huo TL
Chin Med J (Engl); 2016 Dec; 129(24):2926-2935. PubMed ID: 27958224
[TBL] [Abstract][Full Text] [Related]
10. Detection of malignancies with SPECT versus PET, with 2-[fluorine-18]fluoro-2-deoxy-D-glucose.
Martin WH; Delbeke D; Patton JA; Sandler MP
Radiology; 1996 Jan; 198(1):225-31. PubMed ID: 8539384
[TBL] [Abstract][Full Text] [Related]
11. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
12. [Clinical usefulness of FDG-PET in oncology].
Sasaki M
Nihon Igaku Hoshasen Gakkai Zasshi; 2001 Jul; 61(8):414-20. PubMed ID: 11524817
[TBL] [Abstract][Full Text] [Related]
13. Imaging of rats with mammary cancer with two 2-deoxy-2-[18F]fluoro-D-hexoses.
Paul R; Aho K; Bergman J; Haaparanta M; Kulmala J; Reissell A; Solin O
Int J Rad Appl Instrum B; 1989; 16(5):449-53. PubMed ID: 2509402
[TBL] [Abstract][Full Text] [Related]
14. The use of 18F-Fluoro-deoxy-glucose positron emission tomography (18F-FDG PET) as a non-invasive pharmacodynamic biomarker to determine the minimally pharmacologically active dose of AZD8835, a novel PI3Kα inhibitor.
Maynard J; Emmas SA; Ble FX; Barjat H; Lawrie E; Hancox U; Polanska UM; Pritchard A; Hudson K
PLoS One; 2017; 12(8):e0183048. PubMed ID: 28806782
[TBL] [Abstract][Full Text] [Related]
15. Estimation of local cerebral glucose utilization by positron emission tomography: comparison of [18F]2-fluoro-2-deoxy-D-glucose and [18F]2-fluoro-2-deoxy-D-mannose in patients with focal brain lesions.
Wienhard K; Pawlik G; Nebeling B; Rudolf J; Fink G; Hamacher K; Stöcklin G; Heiss WD
J Cereb Blood Flow Metab; 1991 May; 11(3):485-91. PubMed ID: 2016357
[TBL] [Abstract][Full Text] [Related]
16. Neoplasms in a pediatric population: 2-[F-18]-fluoro-2-deoxy-D-glucose PET studies.
Shulkin BL; Mitchell DS; Ungar DR; Prakash D; Dole MG; Castle VP; Hernandez RJ; Koeppe RA; Hutchinson RJ
Radiology; 1995 Feb; 194(2):495-500. PubMed ID: 7824731
[TBL] [Abstract][Full Text] [Related]
17. Hyperglycemia and 18F-FDG PET/CT, issues and problem solving: a literature review.
Finessi M; Bisi G; Deandreis D
Acta Diabetol; 2020 Mar; 57(3):253-262. PubMed ID: 31304560
[TBL] [Abstract][Full Text] [Related]
18. Imaging of canine cancers with 18F-2-fluoro-2-deoxy-D-glucose (FDG) suggests further applications for cancer imaging in man.
Paul R; Johansson R; Kiuru A; Illukka T; Talvio T; Roeda D; Solin O; Söderström KO; Nordman E; Ahonen A
Nucl Med Commun; 1984 Oct; 5(10):641-6. PubMed ID: 6597912
[TBL] [Abstract][Full Text] [Related]
19. Positron emission tomography with 2-[18F]Fluoro-2-deoxy-D-glucose and 16alpha-[18F]fluoro-17beta-estradiol in breast cancer: correlation with estrogen receptor status and response to systemic therapy.
Mortimer JE; Dehdashti F; Siegel BA; Katzenellenbogen JA; Fracasso P; Welch MJ
Clin Cancer Res; 1996 Jun; 2(6):933-9. PubMed ID: 9816253
[TBL] [Abstract][Full Text] [Related]
20. Metabolism of 2-[18F]fluoro-2-deoxyglucose in tumor-bearing rats: chromatographic and enzymatic studies.
Suolinna EM; Haaparanta M; Paul R; Härkönen P; Solin O; Sipilä H
Int J Rad Appl Instrum B; 1986; 13(5):577-81. PubMed ID: 3818323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
